AAAAAA
Results:
1-8
|
Results: 8
Authors:
Voruganti, LNP
Slomka, P
Zabel, P
Mattar, A
Awad, AG
Citation: Lnp. Voruganti et al., Cannabis induced dopamine release: an in-vivo SPECT study, PSYCH RES-N, 107(3), 2001, pp. 173-177
Authors:
Voruganti, L
Slomka, P
Zabel, P
Costa, G
So, A
Mattar, A
Awad, AG
Citation: L. Voruganti et al., Subjective effects of AMPT-induced dopamine depletion in schizophrenia: Correlation between dysphoric responses and striatal D-2 binding ratios on SPECT imaging, NEUROPSYCH, 25(5), 2001, pp. 642-650
Authors:
Voruganti, LNP
Awad, AG
Oyewumi, LK
Cortese, L
Zirul, S
Dhawan, R
Citation: Lnp. Voruganti et al., Assessing health utilities in schizophrenia - A feasibility study, PHARMACOECO, 17(3), 2000, pp. 273-286
Authors:
Awad, AG
Voruganti, LNP
Citation: Ag. Awad et Lnp. Voruganti, Intervention research in psychosis: Issues related to the assessment of quality of life, SCHIZO BULL, 26(3), 2000, pp. 557-564
Authors:
Lapierre, YD
Angus, C
Awad, AG
Saxena, BM
Jones, B
Williamson, P
Vincent, P
Carle, R
Lavallee, YJ
Manchanda, R
Gauthier, B
Wolf, MA
Teehan, MD
Denis, JF
Malla, AK
Oyewumi, LK
Busse, E
Labelle, A
Claesson, L
Grafford, K
Citation: Yd. Lapierre et al., The treatment of negative symptoms: a clinical and methodological study, INT CLIN PS, 14(2), 1999, pp. 101-112
Authors:
Awad, AG
Voruganti, LP
Citation: Ag. Awad et Lp. Voruganti, Cost-utility analysis in schizophrenia, J CLIN PSY, 60, 1999, pp. 22-28
Authors:
Awad, AG
Voruganti, LNP
Citation: Ag. Awad et Lnp. Voruganti, Quality of life and new antipsychotics in schizophrenia - Are patients better off?, INT J SOC P, 45(4), 1999, pp. 268-275
Authors:
Awad, AG
Voruganti, LNP
Citation: Ag. Awad et Lnp. Voruganti, Neuroleptics and quality of life in schizophrenia, QUALITY OF LIFE AND MENTAL HEALTH CARE, 1999, pp. 119-124
Risultati:
1-8
|